AIM: To evaluate the prognostic value of preoperative neutrophil-to-lymphocyte ratio and platelet-lymphocyte ratio in glioblastoma multiforme patients. MATERIAL and METHODS: A total of 75 patients retrospectively analysed. The complete blood count of the patients was analysed before surgery. In our study, cutoff values for PLR 150 (platelet-lymphocyte ratio) and NLR 4 (neutrophil-to-lymphocyte ratio) were found to be significant by creating the ROC curve. Overall survival (OS) was calculated from surgery to death or the last contact. Progression-free survival (PFS) was calculated from surgery to progression. The last follow-up was November 2018. RESULTS: The median OS was significantly shorter in PLR>150 patients (p=0.005; 10 vs 17 months). And the median OS was significantly shorter in NLR>4 patients too (p=0.010; 11 vs 17 months).

No abstract

No abstract

Amaç: Mesane koruyucu tedavi (trimodal tedavi) uygulanan hastalarda nötrofil/lenfosit (NLR) ve trombosit/lenfosit (PLR) oranının prognostik bir değerinin olup olmadığını değerlendirdik. Yöntemler: Bu retrospektif çalışmaya kasa invaze mesane kanseri tanısı alan ve trimodal (TUR + kemoradyoterapi) tedavi uygulanan 40 hasta dahil edildi. Trimodal tedavi uygulanmadan önce NLR ve PLR kan değerlerinden elde edildi. NLR ve PLR değerlerinin sağkalım açısından prognostik değeri olup olmadığı araştırıldı. Bulgular: Trimodal tedavi alan mesane kanserli hastalarda, cinsiyet, yaş, T evresi, radyoterapi dozu, NLR ve PLR değerleri değerlendirildi. Alıcı işletim karakteristiği analizinde NLR için, optimum cutoff değeri 3,2 olarak bulundu. (sensitivite %71,4, spesifite %65,2 p<0,025). Eğri altındaki alan (AUC): 0,717, güven aralığı (CI): %95 (0,557-0,877), PLR için optimum cutoff 152,25 olarak bulundu (sensitivite %78,1, spesifite %64,2, p<0,006). AUC: 0,764, CI: %95 (0,610-0,917). Sağkalım analizlerinde NLR değeri 3,2 üzerinde olan hastalarda hastalıksız sağkalım 52,3±6 ay ve istatiksel olarak anlamlıydı (p=0,023). PLR değerinin 152,25 üzerinde olması hastalıksız sağkalım (52,8±6,1 ay) ve genel sağkalım (50,6±7,2 ay) için bağımsız bir risk faktörü olarak bulundu ve istatiksel olarak anlamlıydı (sırasıyla p=0,043, p=0,011). Sonuç: İnvaziv mesane kanserli hastalarda trimodal tedavi öncesinde NLR ve PLR değeri hastalık progresyonunu göstermek için prognostik bir faktör olarak değerlendirilebilir. Trimodal tedavi kararı verilirken NLR ve PLR değerleri de göz önünde bulundurulmalıdır. Anahtar Kelimeler: Mesane kanseri, kemoradyoterapi, nötrofil/lenfosit oranı, trombosit/lenfosit oranı Introduction: To evaluate whether neutrophil/lymphocyte (NLR) and platelet/lymphocyte (PLR) ratios have prognostic value in patients undergoing bladder conserving treatment (trimodal therapy). Methods: A total of 40 patients receiving trimodality treatment for invasive bladder cancer were included in the study retrospectively. NLR and PLR were obtained for every patient before trimodality treatment was applied. We investigated whether NLR and PLR values had prognostic value for survival. Results: Gender, age, T stage, Histologic grade, radiotherapy dose, NLR and PLR values were evaluated in bladder cancer patients receiving trimodal therapy. In the receiver operating characteristic analysis, the optimum cutoff value for NLR was found to be 3.2 (sensitivity 71.4%, specificity 65.2% p<0.025). Area under the curve (AUC): 0.717, confidence interval (CI) 95% (0.557-0.877), the optimum cutoff for PLR was found as 152.25 (sensitivity 78.1%, specificity 64.2%, p<0.006), AUC: 0.764, CI 95% (0.610-0.917). Survival analysis showed that disease-free survival was 52.36±6 months and statistically significant in patients with an NLR value greater than 3.2 (p=0.023). PLR value above 152.25 was found to be an independent risk factor for disease-free survival (52.8±6.1 months) and overall survival (50.6±7.2 months) (p=0.043, p=0.011, respectively). Conlusion: NLR and PL...

Introduction: The aim of this study was to evaluate whether delayed rectal cancer surgery after long-course neoadjuvant concomitant chemoradiotherapy was effective on pathological complete response (pCR), disease-free survival (DFS), and overall survival (OS). Methods: A total of 112 patients with rectal carcinoma diagnosed at the Radiation Oncology Clinic between 2011 and 2017 were retrospectively analyzed. We compared the outcomes of patients who were operated on greater than >9 weeks (delayed surgery) and less than <8 weeks (early surgery) after completion of neoadjuvant chemoradiotherapy. Results: When we compared the delayed and early surgery groups, pCR rate was higher in the Delayed surgery group (18.2% vs. 5.2%, p=0.032). Tumor regression was found to be close to statistical significance in the delayed surgery group (p=0.050). The decrease in postoperative T stage was found to be statistically significant in the delayed surgery group (p=0.007). When the study was completed, the patient group who underwent delayed surgery had a longer life and this was statistically significant (p=0.044). The OS rate (p=0.004) and DFS rate (p=0.003) was statistically significant in the delayed surgery group. Conclusion: Delaying surgery after neoadjuvant chemoradiotherapy increases the pCR rate, DFS and OS.